During dissemination, cancer cells must face and overcome several physiological borders, including the immediate stroma for local invasion and the endothelium for long-distance metastasis. At these critical junctures, cell plastic...
ver más
31/08/2029
UNIVERSITY OF TURK...
3M€
Presupuesto del proyecto: 3M€
Líder del proyecto
TURUN YLIOPISTO
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Fecha límite participación
Sin fecha límite de participación.
Financiación
concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto
el día 2024-09-01
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto BorderControl
Duración del proyecto: 59 meses
Fecha Inicio: 2024-09-01
Fecha Fin: 2029-08-31
Líder del proyecto
TURUN YLIOPISTO
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
3M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
During dissemination, cancer cells must face and overcome several physiological borders, including the immediate stroma for local invasion and the endothelium for long-distance metastasis. At these critical junctures, cell plasticity between epithelial (E) and mesenchymal (M) states could determine metastasis potential. Based on our preliminary data, ideally-positioned cues emanating from the normal stroma contain the tumour in situ. Once this first border is breached, rare cancer cell-endothelial interactions trigger further dissemination through the vascular border. Moreover, cancer cell plasticity is vital throughout this process, enabling optimal response to distinct border microenvironments. In BorderControl, we will build on our cutting-edge cell biology expertise and close collaboration with clinicians to define the molecular signals underlying these border “crossings” and gain unprecedented information on how cancer cells overwhelm these natural defences. Starting with patient tissues, we will spatially profile the tumour-stroma border to identify receptor-ligand pairs that regulate invasion. We will use microfluidics to image, catch and profile cancer cell crossings at endothelial hotspots and determine key molecular regulators of the process in endothelial and cancer cells. Building on our novel discovery of endosomally regulated E-M cell states, we will test how E-M transitions impact border-breaching potential. These novel concepts will be investigated with interdisciplinary methods (scRNAseq, synthetic biology, colour barcoded HTS) and our new technologies (dynamically tuneable multicell-type migration and invasion imaging platforms) to determine the specific interactions/mechanisms regulating border crossings. Finally, we will take the molecular level discoveries from the cancer-limiting borders back to the patients, assessing clinical relevance using designer TMAs, and expect to uncover novel biomarkers and therapeutically actionable targets.